

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Daviess Community Hospital</p> <p>2. 1314 E Walnut St. P.O. Box 760 Washington, IN 47501</p>	<p>In accordance with letter dated October 02, 2018.</p> <p>3. License number: 13-16138-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: April 30, 2021</p> <p>5. Docket No.: 030-10475 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>
<p style="text-align: center;">CONDITIONS</p> <p>10. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at the licensee's facilities located at 1314 E Walnut St., Washington, Indiana, 47501.</p>		

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-16138-01

Docket or Reference Number

030-10475

Amendment No. 28

11. The Radiation Safety Officer (RSO) for this license is Jonathon Berger, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

James A. Arata, M.D.

10 CFR 35.100,10 CFR 35.200

Jonathon Berger, M.D.

10 CFR 35.100,10 CFR 35.200

John L. Bormann, M.D.

10 CFR 35.100,10 CFR 35.200

Daniel Branam, M.D.

10 CFR 35.100,10 CFR 35.200

Joseph R. Decamp, M.D.

10 CFR 35.100,10 CFR 35.200

Brett A. Hagedorn, M.D.

10 CFR 35.100,10 CFR 35.200

Eric V. Heatwole, M.D.

10 CFR 35.100,10 CFR 35.200

David B. Janizek, M.D.

10 CFR 35.100,10 CFR 35.200

Shawn Johnson, M.D.

10 CFR 35.100,10 CFR 35.200

Christopher Michael Kowalski, M.D.

10 CFR 35.100,10 CFR 35.200

John C. Lacunza, M.D.

10 CFR 35.100,10 CFR 35.200

Vasdev Lohano, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Michael E. Parker, M.D.

10 CFR 35.100,10 CFR 35.200

John Pasalich, M.D.

10 CFR 35.100,10 CFR 35.200

Dakshesh S. Patel, M.D.

10 CFR 35.100,10 CFR 35.200

Randall J. Phillips, M.D.

10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-16138-01

Docket or Reference Number

030-10475

Amendment No. 28

Authorized User(M.D.,D.O.,etc.)Material and Use

John Rock, M.D.

10 CFR 35.100,10 CFR 35.200

Eugene Shih, M.D.

10 CFR 35.100,10 CFR 35.200

Richard W. Sibley, M.D.

10 CFR 35.100,10 CFR 35.200

Rik Stephens, M.D.

10 CFR 35.100,10 CFR 35.200

Andre Byard Stovall, M.D.

10 CFR 35.100,10 CFR 35.200

Pamela Lee Strange, M.D.

10 CFR 35.100,10 CFR 35.200

Marc Thomas, M.D.

10 CFR 35.100,10 CFR 35.200

James C. Wehrenberg, M.D.

10 CFR 35.100,10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 4, 2010 (ML102950531) ☆☆☆☆☆

B. Letter dated March 30, 2011 (ML110900230)

C. Letter dated October 27, 2015 (ML15306A562)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-16138-01

Amendment No. 28

Docket or Reference Number
030-10475

- D. Letter dated February 23, 2016 (ML16056A509)
- E. Letter dated June 28, 2018 (ML18179A410)
- F. Letter dated October 2, 2018 (ML18283B196)
- G. Letter dated January 8, 2019 (ML19008A312)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 8, 2019

By: _____

Colleen Carol Casey
Colleen Carol Casey
Region 3